Toronto general hospital controlled trial data plasma exchange therapy in guillain-barre' syndrome

1985 ◽  
Vol 2 (4) ◽  
pp. 326-331 ◽  
Author(s):  
Kenneth H. Shumak ◽  
John G. Humphrey ◽  
Joseph Y. Chiu ◽  
Margaret L. Routledge ◽  
Marilyn Elphick ◽  
...  
Keyword(s):  
Plasma Exchange ◽  
General Hospital ◽  
Toronto General Hospital ◽  
Controlled Trial ◽  
Trial Data ◽  
Guillain Barre Syndrome ◽  
Plasma Exchange Therapy ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

The acute phase reactant, fibrinogen, as a guide to plasma exchange therapy for acute Guillain-Barré syndrome

2006 ◽  
Vol 21 (2) ◽  
pp. 105-110 ◽  
Author(s):  
Rashmi Sanjay ◽  
Janice Flanagan ◽  
Donata Sodano ◽  
Kenneth C. Gorson ◽  
Allan H. Ropper ◽  
...  
Keyword(s):  
Plasma Exchange ◽  
Acute Phase ◽  
Acute Phase Reactant ◽  
Guillain Barre Syndrome ◽  
Plasma Exchange Therapy ◽  
Phase Reactant ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

Guillain-Barre syndrome: Quantitative measurement of plasma exchange therapy

Neurology ◽  
1987 ◽  
Vol 37 (5) ◽  
pp. 837-837 ◽  
Author(s):  
M. Farkkila ◽  
E. Kinnunen ◽  
E. Haapanen ◽  
M. Iivanainen
Keyword(s):  
Plasma Exchange ◽  
Quantitative Measurement ◽  
Guillain Barre Syndrome ◽  
Plasma Exchange Therapy ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barré syndrome

2000 ◽  
Vol 26 (8) ◽  
pp. 1094-1100 ◽  
Author(s):  
H. Espérou ◽  
M.-C. Jars-Guincestre ◽  
F. Bolgert ◽  
J.-C. Raphaël ◽  
I. Durand-Zaleski
Keyword(s):  
Cost Analysis ◽  
Plasma Exchange ◽  
Guillain Barre Syndrome ◽  
Plasma Exchange Therapy ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

Functional outcomes following inpatient rehabilitation of guillain-barré syndrome patients: Intravenous immunoglobulins versus plasma exchange

2021 ◽  
pp. 1-9
Author(s):  
Moshe Bondi ◽  
Einat Engel-Haber ◽  
Julie Wolff ◽  
Liza Grosman-Rimon ◽  
Ayala Bloch ◽  
...  
Keyword(s):  
Activities Of Daily Living ◽  
Plasma Exchange ◽  
Functional Outcomes ◽  
Daily Living ◽  
Functional Independence ◽  
Assessment Tools ◽  
Guillain Barre Syndrome ◽  
Disability Scale ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

BACKGROUND: Treatment with either Intravenous immunoglobulin (IVIg) or plasma exchange (PE) in patients with Guillain-Barré Syndrome (GBS) showed equivalent efficacy as attested by a commonly used disability scale. However, it has been suggested that this scale may not be sensitive enough to detect subtle functional changes between the two treatments since it mainly focuses on walking capability and respiratory function. OBJECTIVE: To evaluate functional outcomes following treatment with IVIg or PE using comprehensive scales that incorporate parameters of basic activities of daily living. METHODS: A retrospective cohort study was conducted between 2007 and 2013 in an inpatient neurologic rehabilitation department. The study group included 70 individuals with GBS: 39 were treated with PE and 31 with IVIg. A comparison of functional outcomes was performed using Functional Independence Measure (FIM), rehabilitation efficiency (REy), rehabilitation effectiveness (REs), and the GBS disability scale (GDS). RESULTS: Both treatments had a comparable effect on the various functional outcomes. Patients showed a significant increase in total FIM scores (30 points on average) during rehabilitation mainly as a result of an increase in motor sub-scores. A mean improvement of 1.23 (SD 0.9) in GDS was also observed. On average, individuals with GBS spent 20 days combined in the acute departments and 61 days in the rehabilitation department, with length of stay being similar for both treatments. CONCLUSIONS: IVIg and PE treatments have similar basic activities of daily living (ADL) functional outcomes. Nevertheless, due to the different mechanism of actions of these treatments and the multitude of GBS variants, it is possible that further comprehensive assessment tools may demonstrate differences in activity and participation of individuals with GBS.

A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barre syndrome

Neurology ◽  
2003 ◽  
Vol 61 (9) ◽  
pp. 1282-1284 ◽  
Author(s):  
J. Pritchard ◽  
I. A. Gray ◽  
Z. R. Idrissova ◽  
B. R.F. Lecky ◽  
I. J. Sutton ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Interferon Beta ◽  
Controlled Trial ◽  
Guillain Barre Syndrome ◽  
Recombinant Interferon ◽  
Randomized Controlled ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

Plasma Exchange as a Therapy for Guillain-Barré Syndrome with Immune Complexes

Vox Sanguinis ◽  
1981 ◽  
Vol 41 (2) ◽  
pp. 74-78 ◽  
Author(s):  
M. Valbonesi ◽  
S. Garelli ◽  
L. Mosconi ◽  
D. Zerbi ◽  
I. Celano
Keyword(s):  
Plasma Exchange ◽  
Immune Complexes ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré
Sign in / Sign up

Export Citation Format

Share Document